| Zacks Company Profile for Rigel Pharmaceuticals, Inc. (RIGL : NSDQ) |
|
|
| |
| • Company Description |
| Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Number of Employees: 164 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $19.60 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 195,772 shares |
| Shares Outstanding: 17.87 (millions) |
| Market Capitalization: $350.30 (millions) |
| Beta: 1.26 |
| 52 Week High: $29.82 |
| 52 Week Low: $8.61 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-7.98% |
-11.43% |
| 12 Week |
16.32% |
-2.16% |
| Year To Date |
16.53% |
9.13% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
611 GATEWAY BOULEVARD SUITE 900
-
SOUTH SAN FRANCISCO,CA 94080
USA |
ph: 650-624-1100
fax: 650-624-1101 |
ir@rigel.com |
http://www.rigel.com |
|
|
| |
| • General Corporate Information |
Officers
Raul R. Rodriguez - Chief Executive Officer and Director
Gregg Lapointe - Chairman
Dean L. Schorno - Chief Financial Officer
Kamil Ali-Jackson - Director
Alison L. Hannah - Director
|
|
Peer Information
Rigel Pharmaceuticals, Inc. (GSAC)
Rigel Pharmaceuticals, Inc. (CASI)
Rigel Pharmaceuticals, Inc. (ALCD.)
Rigel Pharmaceuticals, Inc. (OMNN)
Rigel Pharmaceuticals, Inc. (CGPI.)
Rigel Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 766559702
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 17.87
Most Recent Split Date: 6.00 (0.10:1)
Beta: 1.26
Market Capitalization: $350.30 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.25 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $2.25 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
